Nuvation Bio (NUVB) Long-Term Investments (2020)
Nuvation Bio (NUVB) posted quarterly Long-Term Investments of $143.8 million for Q4 2020, little changed quarter-over-quarter from $143.8 million in Q3 2020.
Nuvation Bio (NUVB) Long-Term Investments (2020) Analysis & Trends
Nuvation Bio (NUVB) has reported Long-Term Investments for 1 consecutive years, with $143.8 million the latest figure, recorded in Q4 2020.
- In Q4 2020, Long-Term Investments changed N/A year-over-year to $143.8 million; the TTM figure through Dec 2020 stood at $143.8 million (changed N/A YoY), while the FY2020 annual figure was $143.8 million, changed N/A from the prior year.
- Long-Term Investments held at $143.8 million in Q4 2020 per NUVB's latest filing, from $143.8 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $143.8 million in Q4 2020 and bottomed at $143.8 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 143.76 Mn |
| Sep 30, 2020 | 143.75 Mn |